Program
BCTRG 2018 Program
Print Full program| Time | Session/Lecture info |
|---|---|
| 08:30-09:00 | Gathering + coffee
|
| 09:00-09:40 | Opening Session
|
| 09:00-09:10 |
Bella Kaufman and Moshe Oren
Greetings
|
| 09:10-09:40 |
Maurizio Scaltriti , Memorial Sloan Kettering Cancer Center
Introduced by Sima Lev Personalized medicine in breast cancer: ready for prime time
|
| 09:40-10:40 | Session 1
Chair: Maya Dadiani |
| 09:40-10:00 |
Sima Lev, Weizmann Institute of Science
Combination therapy and drug resistance in triple negative breast cancer
|
| 10:00-10:20 |
Ella Evron, Assaf Harofeh Medical Center
DeltaNp73 may facilitate cancer susceptibility in BRCA mutated mammary epithelial cells
|
| 10:20-10:40 |
Amir Sonnenblick, Hadassah Medical Center
Dissecting the Akt/mTOR pathway in estrogen receptor positive breast cancers
|
| 10:40-11:00 | Coffee break
|
| 11:00-12:20 | Session 2
Chair: Sima Lev |
| 11:00-11:20 |
Noa Ben-Baruch, Kaplan Medical Center
The challenge of accurately treating HR positive, HER2 negative early breast cancer. Prospective outcome by using the 21 gene recurrence score
|
| 11:20-11:40 |
Rinat Yerushalmi and Annat Raiter, Rabin Medical Center
Breast cancer treatment decisions: from clinic to bench
|
| 11:40-12:00 |
Neta Erez, Tel Aviv University
Cancer-Associated Fibroblasts Link Tissue Damage with Tumor-Promoting Inflammation in Breast Cancer
|
| 12:00-12:20 |
Ruth Scherz-Shouval, Weizmann Institute of Science
Transcriptional rewiring by stress responses in the breast tumor microenvironment
|
| 12:20-13:30 | Lunch
|
| 13:30-14:00 | |
| 13:30-14:00 |
Karen Gelmon , Vancouver Cancer Centre and University of British Columbia
Introduced by Bella Kaufman The Difficulties of Moving from Bench to Guidelines- Targeting BRCA
|
| 14:00-15:00 | Session 3
Chair: Ruth Scherz-Shouval |
| 14:00-14:20 |
Yuval Shaked, Technion
The host immunological response to cancer therapy: towards precision medicine
|
| 14:20-14:40 |
Maya Dadiani, Sheba Medical Center
Longitudinal transcriptomic patterns through the course of disease
|
| 14:40-15:00 |
Einav Gal-Yam , Sheba Medical Center
High Prevalence of ESR1 mutations in local recurrence of hormone-positive breast cancer
|
| 15:00-16:00 | Discussion groups
|
| 15:00-16:00 |
Yoav Shaul and Shani Paluch Shimon
Omics and personalized medicine
|
| 15:00-16:00 |
Adit Ben-Baruch and Ido Wolf
Immunotherapy and tumor microenvironment
|
| 15:00-16:00 |
Dalit Barkan and Einav Gal-Yam
Resistance to therapy, tumor dormancy and liquid biopsies
|